Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Laboratorios Farmaceuticos ROVI SA
EPS (Diluted)
Laboratorios Farmaceuticos ROVI SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
EPS (Diluted)
€2
|
CAGR 3-Years
-1%
|
CAGR 5-Years
30%
|
CAGR 10-Years
18%
|
|
|
Almirall SA
MAD:ALM
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-32%
|
|
|
F
|
Faes Farma SA
MAD:FAE
|
EPS (Diluted)
€0
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
Laboratorio Reig Jofre SA
MAD:RJF
|
EPS (Diluted)
€0
|
CAGR 3-Years
29%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
L
|
Labiana Health SA
MAD:LAB
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Laboratorios Farmaceuticos ROVI SA
Glance View
Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.
See Also
What is Laboratorios Farmaceuticos ROVI SA's EPS (Diluted)?
EPS (Diluted)
2.7
EUR
Based on the financial report for Dec 31, 2024, Laboratorios Farmaceuticos ROVI SA's EPS (Diluted) amounts to 2.7 EUR.
What is Laboratorios Farmaceuticos ROVI SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
18%
Over the last year, the EPS (Diluted) growth was -17%. The average annual EPS (Diluted) growth rates for Laboratorios Farmaceuticos ROVI SA have been -1% over the past three years , 30% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet